Business News • PR NewsWire • Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial

Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial

Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial

CHAPEL HILL, N.C., May 7, 2011 /PRNewswire/ -- Cempra Pharmaceuticals, a developer of differentiated antibiotics, today announced an oral presentation showing that intravenous (IV) solithromycin demonstrates excellent tolerability and a favorable pharmacokinetic (PK) profile at IV doses up to 800 mg

View More : http://www.prnewswire.com/news-releases/intravenous-iv-administration-of-cempra-pharmaceuticals-solithromycin-cem-101-de...

Releted News by prnewswire

SuKarne Inaugurates Livestock Facilities in Managua With Planned Investment of US$ 100 Million

Mohawk Industries, Inc. anuncia sus utilidades del primer trimestre

Objet to Showcase Exceptionally Detailed and Accurate Dental Models at LMT LAB DAY West

Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial